July 1, 2020 / Ameriderm Research
Ameriderm Research announces it is enrolling patients in a new clinical trial. This trial is for patients aged 12 to 54 with moderate to severe atopic dermatitis. It involves administering injected medication co-administered with vaccination to tetanus and to meningitis. This is as a double-blind, randomized, placebo treatments controlled for 16 weeks with an 8 week follow up.
The trial is expected to enroll quickly.
CALL TODAY (386) 523-0768 to see if you qualify.